BRPI0519439A2 - heteroarilacetamidas - Google Patents

heteroarilacetamidas

Info

Publication number
BRPI0519439A2
BRPI0519439A2 BRPI0519439-3A BRPI0519439A BRPI0519439A2 BR PI0519439 A2 BRPI0519439 A2 BR PI0519439A2 BR PI0519439 A BRPI0519439 A BR PI0519439A BR PI0519439 A2 BRPI0519439 A2 BR PI0519439A2
Authority
BR
Brazil
Prior art keywords
heteroarylacetamides
medicines
novel
formula
well
Prior art date
Application number
BRPI0519439-3A
Other languages
English (en)
Inventor
Markus Boehringer
Narendra Panday
Fabienne Ricklin
Katrin Groebke Zbinden
Wolfgang Haap
Hans Hilpert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0519439A2 publication Critical patent/BRPI0519439A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

HETEROARILACETAMIDAS. A presente invenção refere-se a novas heteroarilacetamidas de fórmula R^ d^-C(O)-N(R^ e^)-R^ c^-CH~ 2~-C(O)-(R^ a^)(R^ b^), na qual R^ a^ a R^ c^ são conforme definidos no relatório descritivo e nas reivindicações, assim como seus sais fisiologicamente aceitáveis. Esses compostos inibem a fator de coagulação Xa e podem ser usados como medicamentos.
BRPI0519439-3A 2004-12-23 2005-12-14 heteroarilacetamidas BRPI0519439A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106943 2004-12-23
PCT/EP2005/013460 WO2006066778A2 (en) 2004-12-23 2005-12-14 Novel heteroarylacetamides

Publications (1)

Publication Number Publication Date
BRPI0519439A2 true BRPI0519439A2 (pt) 2009-01-20

Family

ID=36177975

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519439-3A BRPI0519439A2 (pt) 2004-12-23 2005-12-14 heteroarilacetamidas

Country Status (14)

Country Link
US (2) US7361672B2 (pt)
EP (1) EP1846381B1 (pt)
JP (1) JP4954895B2 (pt)
KR (1) KR20070089245A (pt)
CN (1) CN101124208B (pt)
AT (1) ATE396979T1 (pt)
AU (1) AU2005318538A1 (pt)
BR (1) BRPI0519439A2 (pt)
CA (1) CA2591117C (pt)
DE (1) DE602005007270D1 (pt)
ES (1) ES2308581T3 (pt)
MX (1) MX2007007486A (pt)
RU (1) RU2007128065A (pt)
WO (1) WO2006066778A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
JP2012501334A (ja) * 2008-08-29 2012-01-19 トランス テック ファーマ，インコーポレイテッド 置換アミノチアゾール誘導体、医薬組成物、および使用の方法
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
US20180282331A1 (en) 2015-11-09 2018-10-04 Wockhardt Limited 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
DK1202733T3 (da) 1999-08-12 2005-10-31 Pharmacia Italia Spa 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
WO2001036386A1 (en) 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Diabetic remedy containing dipiperazine derivative
DE10137163A1 (de) * 2001-07-30 2003-02-13 Bayer Ag Substituierte Isoindole und ihre Verwendung
AU2003279735A1 (en) 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
ATE432922T1 (de) * 2004-10-29 2009-06-15 Schering Corp Substituierte 5-carboxyamidpyrazoles und ä1,2, 4ütriazole als viruzide

Also Published As

Publication number Publication date
WO2006066778A2 (en) 2006-06-29
EP1846381A2 (en) 2007-10-24
US7718659B2 (en) 2010-05-18
EP1846381B1 (en) 2008-05-28
CN101124208A (zh) 2008-02-13
CN101124208B (zh) 2011-07-06
ES2308581T3 (es) 2008-12-01
AU2005318538A1 (en) 2006-06-29
US20060142362A1 (en) 2006-06-29
CA2591117C (en) 2014-04-22
JP2008525337A (ja) 2008-07-17
DE602005007270D1 (de) 2008-07-10
CA2591117A1 (en) 2006-06-29
RU2007128065A (ru) 2009-01-27
MX2007007486A (es) 2007-07-20
WO2006066778A3 (en) 2006-08-10
US20080146550A1 (en) 2008-06-19
ATE396979T1 (de) 2008-06-15
US7361672B2 (en) 2008-04-22
JP4954895B2 (ja) 2012-06-20
KR20070089245A (ko) 2007-08-30

Similar Documents

Publication Publication Date Title
UA108363C2 (uk) Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
EA201000105A1 (ru) Химические соединения
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
ECSP088549A (es) Nuevos derivados de pirrol fusionado
JO3018B1 (ar) مُركبات 4- أريل- 1 , 4 – ثنائي هيدرو -1 , 6- نافثيريدين أميد amides مُستبدلة وإستعمالها
BRPI0513379A (pt) derivados de sulfonamida
BR0207726A (pt) Sais farmacêuticos
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
CY1114272T1 (el) Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
BR0316508A (pt) Derivados de ácido mandélico
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
CO6362017A2 (es) Peptidos antivirales terapeuticos
EA201100255A1 (ru) 5-алкинилпиримидины
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
BRPI0815547B8 (pt) composição farmacêutica compreendendo depsipeptídeos cíclicos, e seus usos
TW200720270A (en) Novel cyclic amines
EA201100254A1 (ru) Новые соединения
CR11173A (es) Forma cristalina de [3-(4,5-dihidro-3-isoxazolil)-2-metil-4-(metilsulfonil)fenil]-(5-hidroxi-1-metil-1h-pirazol-4-il) metanona

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]